Lead Product(s) : Ralinepag
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mini-symposia to focus on long-term extension data for the Tyvaso® ® (treprostinil) Inhalation Solution INCREASE study, the ralinepag phase 2 study, and the Orenitram® FREEDOM-EV study.
Product Name : APD811
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Ralinepag
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable